Cardiovascular risk biomarkers in CKD: The inflammation link and the road less traveled

International Urology and Nephrology

Volumn 44, Issue 6, 2012, Pages 1731-1744

  Elewa, Usama ^a   Sanchez Niño, Maria Dolores ^b   Martin Cleary, Catalina ^a   Fernandez Fernandez, Beatriz ^a   Egido, Jesus ^a   Ortiz, Alberto ^a,c  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Cardiovascular disease; Chronic kidney disease; Inflammation; Interleukin 6; Outcomes

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIFEDIOL; CHEMOKINE RECEPTOR CCR5; FIBROBLAST GROWTH FACTOR 23; INTERLEUKIN 6; LIOTHYRONINE; N(G),N(G) DIMETHYLARGININE; PARATHYROID HORMONE;

ACUTE PHASE RESPONSE; BONE DISEASE; CARDIOVASCULAR RISK; CCR5 GENE; CHRONIC KIDNEY DISEASE; DECISION MAKING; HUMAN; INFLAMMATION; KIDNEY FAILURE; MINERAL AND BONE DISORDER; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROTEIN TARGETING; RECEPTOR GENE; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84877633613     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0271-4     Document Type: Review

References (117)

1. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, Wetzels JF, Rosendaal FR, Dekker FW (2009) Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302:1782-1789
2. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr (1998) Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32:853-906
3. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E (2005) German diabetes and dialysis study investigators. atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248
4. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E (2011) Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 80:572-586
5. Ortiz A, Massy ZA, Fliser D, Lindholm B, Wiecek A, Martínez- Castelao A, Covic A, Goldsmith D, Süleymanlar G, London GM, Zoccali C (2011) Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat Rev Nephrol 8:141-150
6. Mischak H, Ioannidis JP, Argiles A, Attwood TK, Bongcam-Rudloff E, Broenstrup M, Charonis A, Chrousos GP, Delles C, Dominiczak A, Dylag T, Ehrich J, Egido J, Findeisen P, Jankowski J, Johnson RW, Julien BA, Lankisch T, Leung HY, Maahs D, Magni F, Manns MP, Manolis E, Mayer G, Navis G, Novak J, Ortiz A, Persson F, Peter K, Riese HH, Rossing P, Sattar N, Spasovski G, Thongboonkerd V, Vanholder R, Schanstra JP, Vlahou A (2012) Implementation of proteomic biomarkers: making it work. Eur J Clin Invest 42:1027-1036
7. Wanner C, Richardson D, Fouque D, Stenvinkel P (2007) OPTA - influence of inflammation/infection on anaemia therapy in haemodialysis patients Nephrol. Dial Transpl 22:iii7-iii12
8. Meuwese CL, Stenvinkel P, Dekker FW, Carrero JJ (2011) Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nat Rev Nephrol 7:166-176
9. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695
10. Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, Sprague SM, Goldfarb S (2010) KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 55:773-799
11. Jones SA, Scheller J, Rose-John S (2011) Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 121:3375-3383
12. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126
13. Brevetti G, Giugliano G, Brevetti L, Hiatt WR (2010) Inflammation in peripheral artery disease. Circulation 122:1862-1875
14. Schiffrin EL, Lipman ML, Mann JF (2007) Chronic kidney disease: effects on the cardiovascular system. Circulation 116:85-97
15. Levi M, van der Poll T, Büller HR (2004) Bidirectional relation between inflammation and coagulation. Circulation 109:2698-2704
16. Paoletti R, Gotto AM Jr, Hajjar DP (2004) Inflammation in atherosclerosis and implications for therapy. Circulation 109:III20-III26
17. Selye H, Grasso S, Dieudonne JM (1961) On the role of adjuvants in calciphylaxis. Rev Allergy 15:461-465
18. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195-2207
19. Muñoz-García B, Martín-Ventura JL, Martínez E, Sánchez S, Hernández G, Ortega L, Ortiz A, Egido J, Blanco-Colio LM (2006) Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 37:2044-2053
20. Rodrigues Díez R, Rodrigues-Díez R, Lavoz C, Rayego-Mateos S, Civantos E, Rodríguez-Vita J, Mezzano S, Ortiz A, Egido J, Ruiz-Ortega M (2011) Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process. PLoS ONE 5:e14145
21. Rodríguez-Vita J, Sánchez-Galán E, Santamaría B, Sánchez-López E, Rodrigues-Díez R, Blanco-Colio LM, Egido J, Ortiz A, Ruiz-Ortega M (2008) Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation. PLoS ONE 3:e3959
22. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J (2008) Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 111:S4-S9
23. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ (2008) Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int 73:1406-1412
24. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR (2008) C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118:2243-2251
25. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E (2009) Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 25:567-579
26. Ridker PM, Macfadyen JG, Nordestgaard BG, Koenig W, Kastelein JJ, Genest J, Glynn RJ (2010) Rosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5 % to 10 % and 10 % to 20 % 10-year risk. Implications of the justification for use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) trial for "intermediate risk". Circ Cardiovasc Qual Outcomes 3:447-452
27. Anavekar NS, Pfeffer MA (2004) Cardiovascular risk in chronic kidney disease. Kidney Int Suppl 92:S11-S15
28. Apple FS, Murakami MM, Pearce LA, Herzog CA (2004) Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 50:2279-2285
29. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL (1998) Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32:107-114
30. Tripepi G, Mallamaci F, Zoccali C (2005) Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 16:S83-S88
31. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B (2006) Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 47:139-148
32. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, Bertini A, Sposini S, Perez-Garcia R, Rindi P, Palla R, Tetta C (2004) Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transpl 19:1154-1160
33. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V (2008) Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 5:e78
34. Meuwese CL, Snaedal S, Halbesma N, Stenvinkel P, Dekker FW, Qureshi AR, Barany P, Heimburger O, Lindholm B, Krediet RT, Boeschoten EW, Carrero JJ (2011) Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-α are similarly associated with survival in haemodialysis patients. Nephrol Dial Transpl 26:1313-1318
35. Zoccali C, Tripepi G, Mallamaci F (2006) Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol 17:S169-S173
36. Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, Bárány P, Heimbürger O, Marrón B, Metry G, Snaedal S, Lindholm B, Egido J, Stenvinkel P, Blanco-Colio LM (2009) Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 4:110-118
37. Justo P, Sanz AB, Sanchez-Niño MD, Winkles JA, Lorz C, Egido J, Ortiz A (2006) Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int 70:1750-1758
38. Sanz AB, Justo P, Sanchez-Niño MD, Blanco-Colio LM, Winkles JA, Kreztler M, Jakubowski A, Blanco J, Egido J, Ruiz-Ortega M, Ortiz A (2008) The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 19:695-703
39. Sanz AB, Sanchez-Niño MD, Ortiz A (2011) TWEAK, a multifunctional cytokine in kidney injury. Kidney Int 80:708-718
40. Lavín-Gómez BA, Palomar-Fontanet R, Gago-Fraile M, Quintanar-Lartundo JA, Gómez-Palomo E, González-Lamuño D, García-Unzueta MT, Arias-Rodríguez MA, Gómez-Gerique JA (2011) Inflammation markers, chronic kidney disease, and renal replacement therapy. Adv Perit Dial 27:33-37
41. Inoue K, Kodama T, Daida H (2012) Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. Int J Vasc Med 2012:657025
42. Ikizler TA, Hakim RM (1996) Nutrition in end-stage renal disease. Kidney Int 50:343-357
43. Daveau M, Davrinche C, Djelassi N, Lemetayer J, Julen N, Hiron M, Arnaud P, Lebreton JP (1999) Partial hepatectomy and mediators of inflammation decrease the expression of liver alpha 2-HS glycoprotein gene in rats. FEBS Lett 273:79-81
44. Jahnen-Dechent W, Heiss A, Schäfer C, Ketteler M (2011) Fetuin-A regulation of calcified matrix metabolism. Circ Res 108:1494-1509
45. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J (2003) Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361:827-833
46. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393-4408
47. Drechsler C, Verduijn M, Pilz S, Krediet RT, Dekker FW, Wanner C, Ketteler M, Boeschoten EW, Brandenburg V, NECOSAD Study Group (2011) Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 6:1752-1759
48. Regidor DL, Kovesdy CP, Mehrotra R, Rambod M, Jing J, McAllister CJ, Van Wyck D, Kopple JD, Kalantar-Zadeh K (2008) Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 19:2193-2203
49. Bergwitz C, Jüppner H (2010) Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 61:91-104
50. Cozzolino M, Ciceri P, Volpi EM, Olivi L, Messa PG (2009) Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease. Blood Purif 27:338-344
51. Krajisnik T, Olauson H, Mirza MA, Hellman P, Akerström G, Westin G, Larsson TE, Björklund P (2010) Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 78:1024-1032
52. Fraser WD (2009) Hyperparathyroidism. Lancet 374:145-158
53. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes(KDIGO) (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 11:1945-1953
54. Torres PU (2006) The need for reliable serum parathyroid hormone measurements. Kidney Int 70:240-243
55. Eknoyan G, Levin A, Levin NW (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1-201
56. Steddon S, Sharples E. Renal Association (2010) CKD-Mineral and Bone Disorders (CKD-MBD) clinical practice guidelines, 5th edition. http://www.renal.org/Clinical/GuidelinesSection/CKD-MBD.aspx. Accessed 22 Aug 2012
57. Guidelines 1. Evaluation of calcium and phosphorous metabolism (2007) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S52-S57
58. Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium (2009) KDIGO Clinical practice guidelines for diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 76:S50-S90
59. Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL (2009) Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 53:S3-S10
60. Rojas-Rivera J, De La Piedra C, Ramos A, Ortiz A, Egido J (2010) The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transpl 25:2850-2865
61. Mucsi I, Almási C, Deák G, Marton A, Ambrus C, Berta K, Lakatos P, Szabó A, Horváth C (2005) Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol 64:288-294
62. Wolf M, Thadhani R (2007) Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. J Steroid Biochem Mol Biol 103:487-490
63. Sanchez-Niño MD, Bozic M, Córdoba-Lanús E, Valcheva P, Gracia O, Ibarz M, Fernandez E, Navarro-Gonzalez JF, Ortiz A, Valdivielso JM (2012) Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol 302:F647-F657
64. Sanchez-Niño MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, Ruiz-Ortega M, Egido J, Ortiz A (2011) Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transpl 26:1797-1802
65. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A (2010) Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 5:905-911
66. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD (2010) J Am Soc Nephrol 21:353-361
67. John GB, Cheng CY, Kuro-o M (2011) Role of Klotho in aging, phosphate metabolism, and CKD. Am J Kidney Dis 58:127-134
68. Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, Moe OW (2011) Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 22:124-136
69. Moreno JA, Izquierdo MC, Sanchez-Niño MD, Suárez-Alvarez B, Lopez-Larrea C, Jakubowski A, Blanco J, Ramirez R, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A, Sanz AB (2011) The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J Am Soc Nephrol 22:1315-1325
70. Mendoza JM, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, Bazzano LA, Xie D, Kretzler M, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, Wolf M, for the Chronic Renal Insufficiency Cohort (2012) Fibroblast Growth Factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 7:1155-1162
71. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, MMKD Study Group, Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Riegler P (2007) Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study. J Am Soc Nephrol 18:2600-2608
72. Gonzalez-Parra E, Gonzalez-Casaus ML, Galán A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A (2011) Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transpl 26:2567-2571
73. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584-592
74. Beddhu S, Baird B, Ma X, Cheung AK, Greene T (2010) Serum alkaline phosphatase and mortality in hemodialysis patients. Clin Nephrol 74:91-96
75. Tonelli M, Curhan G, Pfeffer M, Sacks F, Thadhani R, Melamed ML, Wiebe N, Muntner P (2009) Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 120:1784-1792
76. Persy VP, McKee MD (2011) Prevention of vascular calcification: is pyrophosphate therapy a solution? Kidney Int 79:490-493
77. de Solis AJ, González-Pacheco FR, Deudero JJ, Neria F, Albalate M, Petkov V, Susanibar L, Fernandez-Sanchez R, Calabia O, Ortiz A, Caramelo C (2009) Alkalinization potentiates vascular calcium deposition in an uremic milieu. J Nephrol 22:647-653
78. Damera S, Raphael KL, Baird BC, Cheung AK, Greene T, Beddhu S (2011) Serum alkaline phosphatase levels associate with elevated serum C-reactive protein in chronic kidney disease. Kidney Int 79:228-233
79. Kalantar-Zadeh K, Kovesdy CP (2009) Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol 4:1529-1539
80. Guerrero F, Montes de Oca A, Aguilera-Tejero E, Zafra R, Rodríguez M, López I (2012) The effect of vitamin D derivatives on vascular calcification associated with inflammation. Nephrol Dial Transpl 27:2206-2212
81. Sigrist MK, Taal MW, Bungay P, McIntyre CW (2007) Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2:1241-1248
82. Kielstein JT, Böger RH, Bode-Böger SM, Schäffer J, Barbey M, Koch KM, Frölich JC (1999) Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10:594-600
83. Zhou QG, Zhou M, Hou FF, Peng X (2009) Asymmetrical dimethylarginine triggers lipolysis and inflammatory response via induction of endoplasmic reticulum stress in cultured adipocytes. Am J Physiol Endocrinol Metab 296:E869-E878
84. Böger RH, Zoccali C (2003) ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl 4:23-28
85. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C (2005) Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16:2449-2455
86. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113-2117
87. Tripepi G, Mattace Raso F, Sijbrands E, Seck MS, Maas R, Boger R, Witteman J, Rapisarda F, Malatino L, Mallamaci F, Zoccali C (2011) Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol 6:1714-1721
88. Nijveldt RJ, Teerlink T, van Guldener C, Prins HA, van Lambalgen AA, Stehouwer CD, Rauwerda JA, van Leeuwen PA (2003) Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrol Dial Transpl 18:2542-2550
89. Zoccali C, Maas R, Cutrupi S, Pizzini P, Finocchiaro P, Cambareri F, Panuccio V, Martorano C, Schulze F, Enia G, Tripepi G, Boger R (2007) Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. Nephrol Dial Transpl 22:801-806
90. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Suzuki T, Ueda Y, Yamada S, Shoji H, Takeuchi M, Ueda S, Matsui T, Adachi H, Okuda S, Yamagishi S (2009) Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock. Pharmacol Res 60:515-518
91. Jiang JL, Wang S, Li NS, Zhang XH, Deng HW, Li YJ (2007) The inhibitory effect of simvastatin on the ADMA-induced inflammatory reaction is mediated by MAPK pathways in endothelial cells. Biochem Cell Biol 85:66-77
92. Zoccali C, Tripepi G, Cutrupi S, Pizzini P, Mallamaci F (2005) Low triiodothyronine: a new facet of inflammation in end-stage renal disease. J Am Soc Nephrol 16:2789-2795
93. Boelen A, Maas MA, Lowik CW, Platvoet MC, Wiersinga WM (1996) Induced illness in interleukin-6 (IL-6) knock-out mice: a causal role of IL-6 in the development of the low 3,5,3′-triiodothyronine syndrome. Endocrinology 137:5250-5254
94. Davies PH, Black EG, Sheppard MC, Franklyn JA (1996) Relation between serum interleukin-6 and thyroid hormone concentrations in 270 hospital in-patients with non-thyroidal illness. Clin Endocrinol (Oxf) 44:199-205
95. Bartalena L, Brogioni S, Grasso L, Velluzzi F, Martino E (1994) Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness. J Endocrinol Invest 17:269-274
96. Hashimoto H, Igarashi N, Miyawaki T, Sato T (1995) Effects of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 on type I iodothyronine 5′-deiodination in rat thyroid cell line, FRTL-5. J Interferon Cytokine Res 15:367-375
97. Warner MH, Beckett GJ (2010) Mechanisms behind the non-thyroidal illness syndrome: an update. J Endocrinol 205:1-13
98. Afandi B, Schussler GC, Arafeh AH, Boutros A, Yap MG, Finkelstein A (2000) Selective consumption of thyroxine-binding globulin during cardiac bypass surgery. Metabolism 49:270-274
99. Carrero JJ, Qureshi AR, Axelsson J, Yilmaz MI, Rehnmark S, Witt MR, Bárány P, Heimbürger O, Suliman ME, Alvestrand A, Lindholm B, Stenvinkel P (2007) Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med 262:690-701
100. Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P (2006) Low triiodothyronine and survival in end-stage renal disease. Kidney Int 70:523-528
101. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Hingorani AD, Casas JP (2012) The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379:1214-1224
102. Muntinghe FL, Verduijn M, Zuurman MW, Grootendorst DC, Carrero JJ, Qureshi AR, Luttropp K, Nordfors L, Lindholm B, Brandenburg V, Schalling M, Stenvinkel P, Boeschoten EW, Krediet RT, Navis G, Dekker FW (2009) CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol 20:1641-1649
103. Rao M, Wong C, Kanetsky P, Girndt M, Stenvinkel P, Reilly M, Raj DS (2007) Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int 72:549-556
104. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM (2010) Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5:286-291
105. Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA (2011) IL-1β receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol 22:437-442
106. Geyer M, Müller-Ladner U (2010) Actual status of antiinterleukin-1 therapies in rheumatic diseases. Curr Opin Rheumatol 22:246-251
107. Radin A, Marbury T, Osgood G, Belomestnov P (2010) Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD). J Clin Pharmacol 50:835-841
108. Dayer JM, Choy E (2010) Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 49:15-24
109. Rossi JF, Négrier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P, Berns B (2010) A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 103:1154-1162
110. Bonsib SM (2009) Renal cystic diseases and renal neoplasms. Clin J Am Soc Nephrol 4:1998-2007
111. Karihaloo A, Koraishy F, Huen SC, Lee Y, Merrick D, Caplan MJ, Somlo S, Cantley LG (2011) Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 22:1809-1814
112. Takakura A, Contrino L, Zhou X, Bonventre JV, Sun Y, Humphreys BD, Zhou J (2009) Renal injury is a third hit promoting rapid development of adult polycystic kidney disease. Hum Mol Genet 18:2523-2531
113. Puchalski T, Prabhakar U, Jiao Q, Berns B, Davis HM (2010) Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 16:1652-1661
114. Woodrick RS, Ruderman EM (2011) Interleukin 6 inhibition - RA and beyond. Bull NYU Hosp Jt Dis 69:225-229
115. Tanaka T, Narazaki M, Kishimoto T (2011) Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett 585:3699-3709
116. http://clinicaltrials.gov/ct2/results?term=tocilizumab+. Accessed 8 Apr 2012
117. Don BR, Kim K, Li J, Dwyer T, Alexander F, Kaysen GA (2010) The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin Nephrol 73:431-438